Pioneering the Future of Cancer Treatment

Dr. Martin Schwill joined Adularia as Head of AI, Bioinformatics, and CADD, bringing a wealth of expertise in computational biochemistry, bioinformatics, and AI-driven drug discovery. With over a decade of experience, he specializes in multi-omics integration, structural biology, and transcriptomics, applying advanced computational methods to pre-clinical research and translational medicine. Martin's academic journey began at the University of Zurich, where he pursued a PhD in Biochemistry under the mentorship of Prof. Plückthun, focusing on anti-cancer protein therapeutics. His postdoctoral research at UZH and the MIT Koch Institute deepened his understanding of cancer drug resistance through multi-omics analysis. Before joining Adularia, Martin played a pivotal role at TOLREMO Therapeutics, where his contributions in bioinformatics and data analysis were instrumental in advancing the small molecule drug TT125-802 to an FDA IND filing. His experience extends across computational drug discovery, machine learning applications and AI modeling in life sciences, and large-scale data analysis, ensuring a seamless integration of AI into biomedical research. At Adularia, Martin leads efforts to apply generative AI, deep learning, and multi-omics approaches to accelerate drug discovery and therapeutic development. His work focuses on computational strategies for small molecules, protein therapeutics, and engineered biologics. As a dedicated scientist with a passion for solving complex challenges, Martin continues to drive innovation at the intersection of AI and life sciences.

Francesca joined the team in June 2023 as a research scientist at Adularia, bringing her deep expertise in cancer biology to the development of novel cancer therapies. She plays a key role in designing and optimizing functional co-culture assays, conducting in vivo studies, and analyzing tumor-immune interactions to advance the company’s therapeutic pipeline. She earned her Master’s degree in Cellular and Molecular Biology from the University of Turin and developed a strong interest in stem cells and tissue bioengineering during her time at Biotis in Bordeaux. Her passion for cancer research led her to pursue a PhD at the University Hospital RWTH Aachen, where she investigated the role of cancer stem cells in breast cancer progression. At Adularia, Francesca applies her scientific rigor and technical expertise to accelerate the preclinical development of next-generation cancer treatments. Outside the lab, she enjoys reading, experimenting in the kitchen, and exploring nature on hikes with friends.

Vasco joined Adularia as a Senior Scientist, bringing expertise in small molecule drug discovery. He holds a PhD in Bioengineering from EPFL and a Master’s in Biology from the University of Basel. Given his background in Cell Biology, Vasco leads the development of high-throughput cell-based screening assays and target characterization assays. In addition, he leads the framework to design and implement preclinical studies, working closely with internal and external collaborators to drive drug candidate validation. Throughout his career, Vasco has worked across diverse disease areas, including Hematology, Immuno-Oncology, and Neurodegeneration. He has contributed to industrial partnerships and academic collaborations, led interdisciplinary research teams, and mentored junior scientists. His expertise in drug discovery has led to the rapid progression of multiple projects from early discovery to in vivo studies. Beyond the lab, Vasco enjoys cultural and culinary explorations, playing football, and seeking out both beaches with big waves and mountains with fresh powder.

In May 2024, Ruxandra joined the Adularia team, taking on the role of Head of Regulatory Affairs and Quality Assurance. With a background as a pharmacist, Ruxandra brings over 9 years of experience in these fields. She initially delved into community pharmacy, gaining first-hand insights into patient needs and challenges. Motivated by a desire to make a broader impact on healthcare, Ruxandra transitioned her career towards obtaining an insider's perspective across various stakeholders, including small pharma companies, Contract Research Organizations (CROs) and consultancies, and even the European Medicines Agency (EMA). Her journey led her to immerse herself in the realm of clinical trials, a domain she is profoundly passionate about due to its potential to bring transformative benefits to patients. At the EMA, Ruxandra was involved in the development of the Clinical Trials Information System (CTIS) and subsequently became a certified EMA CTIS Sponsor Master Trainer, helping sponsors effectively navigate the complexities of the EU Clinical Trials Regulation. Beyond her professional endeavours, Ruxandra dedicates her spare time to nurturing her diverse interests, which include perfumery, gardening, and exploring the beauty of the great outdoors.

Charles-Henry Fabritius is an innovative drug discovery leader with over 15 years of experience in the pharmaceutical and biotechnology industries. He has held key positions at companies such as TOLREMO therapeutics AG and Invasight AG, where he served as Head of Chemistry, and Selvita where he was Discovery Chemistry Director. Throughout his career, Charles-Henry has worked across a broad range of target classes, and has significant experience at all stages of the drug development process, from small molecule discovery to preclinical development. His expertise is further demonstrated by his contributions to several patents. Charles-Henry's extensive experience and innovative approach make him a valuable asset in advancing novel therapeutic solutions in the biotech industry.

Julija joined our team in June 2024 as a Research Scientist, bringing a strong background in immunology and translational research. She holds an MSc in Pharmacy-Medical Biochemistry and began her career at PrimeVigilance, where she focused on clinical trial safety. Driven by a passion for bridging fundamental research with clinical applications, she pursued a Ph.D. at the University of Italian Switzerland. During her doctoral studies at the Translational Research Laboratory EOC in Bellinzona, Julija led a high-impact project investigating adaptive immunity in colorectal cancer, exploring the immunomodulatory potential of commensal gut bacteria to enhance anti-tumor responses. At Adularia, Julija is responsible for developing functional immunological assays to characterize novel drug candidates, contributing to the advancement of immune-based therapies for cancer treatment. Her work is fueled by a deep commitment to scientific innovation and a drive to bring meaningful improvements to patients’ lives. Beyond the research lab, Julija enjoys exploring nature, cooking, and discovering new places - activities that keep her inspired and balanced.